Clinical Trials
20 trialsNCT07286266 2026-05-27
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT07564141 2026-05-04
RAINFOLā¢-07
Genmab
Phase 3 Not yet recruiting
NCT07551778 2026-04-27
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
BOE Technology Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07527858 2026-04-14
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Gilead Sciences
Phase 2 Not yet recruiting
NCT07525206 2026-04-13
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Not yet recruiting
NCT07497074 2026-03-27
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Not yet recruiting
NCT07479485 2026-03-18
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Lepu Biopharma Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT07474727 2026-03-16
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2 Not yet recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07392866 2026-02-09
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2/3 Not yet recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT07370818 2026-01-27
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Onconic Therapeutics Inc.
Phase 2 Not yet recruiting
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06584071 2024-12-16
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Biotheus Inc.
Phase 1/2 Not yet recruiting
NCT06683703 2024-11-12
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT05976568 2023-08-04
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT05798819 2023-04-05
A Study of GLS-010 Plus Platinum-containing ChemotherapyĀ±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3 Not yet recruiting
NCT05715840 2023-02-08
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy Ā± Bevacizumab Versus Placebo Plus Chemotherapy Ā±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPSā„1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting